Many biomarkers including neurotransmitters are found in external body fluids, such as sweat or saliva, but at lower titration levels than they are present in blood. Efficient detection of such biomarkers thus requires, on the one hand, to use techniques offering high sensitivity, and, on the other hand, to use a miniaturized format to carry out diagnostics in a minimally invasive way. Here, we present the hybrid integration of bottom-up silicon-nanowire Schottky-junction FETs (SiNW SJ-FETs) with complementary-metal-oxide-semiconductor (CMOS) readout and amplification electronics to establish a robust biosensing platform with 32 × 32 aptasensor measurement sites at a 100 μm pitch. The applied hetero-junctions yield a selective biomolecular detection down to femtomolar concentrations. Selective and multi-site detection of dopamine is demonstrated at an outstanding sensitivity of ∼1 V/fM. The integrated platform offers great potential for detecting biomarkers at high dilution levels and could be applied, for example, to diagnosing neurodegenerative diseases or monitoring therapy progress based on patient samples, such as tear liquid, saliva, or eccrine sweat.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204155PMC
http://dx.doi.org/10.3389/fnins.2022.875656DOI Listing

Publication Analysis

Top Keywords

multisite dopamine
4
dopamine sensing
4
sensing femtomolar
4
femtomolar resolution
4
resolution cmos
4
cmos enabled
4
enabled aptasensor
4
aptasensor chip
4
chip biomarkers
4
biomarkers including
4

Similar Publications

Article Synopsis
  • Autism spectrum disorder (ASD) is a complex lifelong condition, and this study aimed to create a classifier using resting-state fMRI from a large group of 730 Japanese adults to identify its neural and biological features.
  • The developed classifier showed effectiveness in differentiating individuals with ASD from neurotypical controls across various countries, including the US and Belgium, and it also applied to children and adolescents.
  • Importantly, the study found that the classifier identified crucial functional connections related to social interaction difficulties and neurotransmitter activity, and it linked ASD with similar neurobiological factors seen in ADHD and schizophrenia, enhancing understanding of related mental health disorders.
View Article and Find Full Text PDF

Background: Neuropsychopharmacological compounds may exert complex brain-wide effects due to an anatomically and genetically broad expression of their molecular targets and indirect effects interconnected brain circuits. Electrophysiological measurements in multiple brain regions using electroencephalography (EEG) or local field potential (LFP) depth-electrodes may record fingerprints of such pharmacologically-induced changes in local activity and interregional connectivity (pEEG/pLFP). However, in order to reveal such patterns comprehensively and potentially derive mechanisms of therapeutic pharmacological effects, both activity and connectivity have to be estimated for many brain regions.

View Article and Find Full Text PDF
Article Synopsis
  • Dopamine transporter SPECT (DAT-SPECT) is essential for diagnosing Parkinson's disease (PD), but its accuracy can vary across different clinical sites, posing challenges in multisite trials.
  • Both prospective linear regression and retrospective statistical correction (ComBat) methods were tested to improve the accuracy of DAT-SPECT measurements in distinguishing PD patients from healthy controls.
  • Results indicated that while both correction methods improved diagnostic performance, the ComBat correction achieved comparable accuracy to the prospective method, suggesting it could be an effective alternative for addressing site-related variability.
View Article and Find Full Text PDF

Cancer stem cells (CSCs), functionally characterized by self-renewal and tumor-initiating activity, contribute to decreased tumor immunogenicity, while fostering tumor growth and metastasis. Targeting G9a histone methyltransferase (HMTase) effectively blocks CSC functions in colorectal tumors by altering pluripotent-like molecular networks; however, existing molecules directly targeting G9a HMTase activity failed to reach clinical stages due to safety concerns. Using a stem cell-based phenotypic drug-screening pipeline, we identified the dopamine transporter (DAT) antagonist vanoxerine, a compound with previously demonstrated clinical safety, as a cancer-specific downregulator of G9a expression.

View Article and Find Full Text PDF

Objective: To quantify the benefits versus harms of amantadine in the treatment of irritability and aggression following traumatic brain injury.

Methods: Secondary outcome data from a randomized controlled multisite trial of amantadine 100 mg twice daily were used to calculate number-needed-to-treat (NNT). Given prior findings of positive clinician-perceived effects and low incidence of adverse events, we hypothesized low number-needed-to-treat for benefit (NNTB; high benefit) and high number-needed-to-treat for harm (NNTH; low risk) based on the clinician ratings, supporting the use of amantadine in clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!